Adaptor-based Viral Vector Development Platform
Adaptor-based viral vectors can transduce target cells while avoiding effects on non-target cells. With a research team with extensive expertise in vector engineering services as well as an advanced technology platform, our company is confident in providing customers with adaptor-based viral vector development service for rare diseases therapy research and development and providing one-stop personalized custom service according to the client's specific needs.
Adaptors for Targeting Viral Vectors
Adaptors are molecules with dual specificity, characterized by binding a viral attachment protein at one end and a receptor on the target cell at the other. The fact that different adaptors can be easily coupled to the same vector without the need to alter vector structures that may be detrimental to vector production or gene transfer allows for great flexibility and safety in vector targeting strategies using adaptors. Most adaptors have great potential in gene therapy for rare diseases by ablating the native tropism of viral vectors and conferring a new tropism to the desired target to enable targeted gene delivery.
Fig.1 Concept of LLE adapter-mediated transduction with lentiviral vectors. (Cordes, N., et al., 2022)
Advantages of Adaptor-based Viral Vectors
The use of adapter-based viral vectors has been explored as an alternative approach. Adaptor-based viral vectors use structural knowledge to guide the modification of viral attachment proteins, overcome the shortcomings of pseudotyping of viral vectors, and can break through the limitations of the number of viral attachment proteins and the laborious viral engineering required for each new target. Selective delivery of genes to the cell type of interest using adaptor-based viral vectors is an effective and safe strategy for gene therapy applications.
Our Services
Our company helps customers build adaptor-based viral vector systems, which are selective and flexible targeting systems that restrict gene transfer to the cell type of interest. Our services for targeted viral vectors will improve gene therapy's safety and efficacy for rare diseases. Optional services include but are not limited to:
Receptor-ligand Complex Adaptors Development
Helping customers to genetically fuse viral receptors to the ligands of receptors expressed on target cells to achieve vector targeting. Our company can target adenoviral vectors to dendritic cells by fusing the ectodomain of the adenovirus receptor to CD40L, a ligand for the CD40 receptor on dendritic cells.
Chemically Coupling Adaptors Development
Providing chemically coupling adaptors development services to covalently connect targeting ligands to the vector, including but not limited to:
- PEGylation strategies for the development of targeted AAV and adenoviral vectors.
- Thiol-group coupling systems for the introduction of full-length proteins and receptor ligands (such as fatty acids and small molecules) into non-enveloped vectors.
Avidin-biotin Adaptors Development
The avidin-biotin system is suitable for vector types that can be chemically biotinylated, or that allow the incorporation of a biotin-acceptor peptide (BAP). Our company exploits the high-affinity binding between avidin and biotin to develop adaptor strategies for use with a wide range of viral vectors. We can establish protocols for the biotinylation of adenoviral vectors, AAV vectors, and vaccinia viral vectors for vector targeting.
Monoclonal Antibody Adaptors Development
Helping customers develop monoclonal antibodies to be used as targeting tools for gene transfer vectors. Our company inserts a region of the bacterial immunoglobulin (Ig) binding protein into the viral attachment proteins of multiple vector systems to specifically bridge to target receptors via antibody specificity.
Peptide Adaptors Development
Providing peptide adaptors development by directing vectors to different cellular receptors. Redirection of peptides can be achieved by specifically connecting customized peptides to cell surface proteins through gene integration, chemical peptide coupling, or bifunctional adapter molecule bridging.
Project Workflow
As an integrated CRO, our development services for adaptor-based vector systems for targeted gene therapy provide the added flexibility to find the option that better suits your rare disease gene therapy development program. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Cordes, N., et al. "Adapter-Mediated Transduction with Lentiviral Vectors: A Novel Tool for Cell-Type-Specific Gene Transfer." Viruses 14.10 (2022): 2157.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
